Cortisone Acetate

(Cortisone)

Phase 3Small molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cortisone Acetate is one of 109 small molecule programs targeting Plantar Fasciitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

108

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Plantar FasciitisActive, not recruiting

Low Back PainActive, not recruiting

Rotator Cuff TearActive, not recruiting

OsteoarthritisActive, not recruiting

Plantar FasciitisPreclinical

Active, not recruiting

Low Back PainPhase 3

Active, not recruiting

Rotator Cuff TearPreclinical

Active, not recruiting

OsteoarthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Cortisone Acetate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Toradol

Roche

Preclinical

1 5

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 6

Cataflam

Bayer Aspirin

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Plantar Fasciitis

NCT02196155

Clinical

Trials by Indication[1]

Osteoarthritis3 trials

Non-surgical Treatment of Knee Osteoarthritis - a Comparison of Effects in 2200 Patients

Completed·NNorthern Orthopaedic Division, Denmark··NCT02091830·2,262 enrolled

BMA vs Cortisone for Glenohumeral Osteoarthritis

Completed·WWomen's College Hospital·Phase 2/3·NCT03580148·34 enrolled

Is Botox Effective in Relieving Pain From Knee Osteoarthritis?

Completed·MMayo Clinic·Phase 1·NCT00279903·62 enrolled

Low back pain1 trial

Effectiveness of Facet Joint Infiltration in Low Back Pain

Unknown status·FFederal University of São Paulo·Phase 3·NCT01447160·60 enrolled

Pilot Study1 trial

Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study

Completed·SScott and White Hospital & Clinic·Phase 4·NCT02639039·50 enrolled

Rotator Cuff Tear1 trial

Safety and Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears

Completed·IInGeneron, Inc.·N/A·NCT02918136·18 enrolled

Arthroscopy1 trial

Comparative, Randomized Study on the Anti-inflammatory and Regenerative Efficacy of a New Medical Device (DM) Based on Hydrolyzed Collagen Peptides in Patients With Femoro-acetabular Impingement Undergoing Hip Arthroscopy

Completed·IIstituto Ortopedico Rizzoli·N/A·NCT06082271·25 enrolled

1 more indication

Plantar Fasciitis1 trial

Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis

Recruiting·IInsel Gruppe AG, University Hospital Bern·N/A·NCT02196155·54 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

CORTISONE ACETATE

NDA NDA008126

Jan 1, 1982

CORTONE

NDA NDA007110

Jan 1, 1982

CORTISONE ACETATE

NDA NDA009458

Jan 1, 1982

CORTISONE ACETATE

NDA NDA008284

Jan 1, 1982

CORTONE

NDA NDA007750

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Cortisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cortisone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cortisone. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA008126). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cortisone Acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Osteoarthritis3 trials

Low back pain1 trial

Pilot Study1 trial

Rotator Cuff Tear1 trial

Arthroscopy1 trial

Plantar Fasciitis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News